Every financial statement,
one clean chart.
Search any US-listed company. Data straight from SEC filings.
IMMUNITYBIO, INC. (IBRX), most recent 12 months reported: revenue $165.79M, net loss $992.36M, free cash flow -$288.51M. Latest balance sheet on file: liquid cash $357.37M, total debt $1.19B, net cash -$832.07M. From SEC filings. More on IMMUNITYBIO, INC.: Revenue · Profitability · Cash flow · Debt Others in Biological Products, (No Diagnostic Substances): VERICEL CORPORATION · Vir Biotechnology, Inc. · Vaxart, Inc. · REGENXBIO Inc. · Beam Therapeutics Inc. · AGENUS INC · ATARA BIOTHERAPEUTICS, INC. · Autolus Therapeutics plc
Filter every US company by the numbers — net cash, margins, ROIC, growth. Looking for one company? The search box above is free.
Follow a company and we'll email you when it files a quarterly or annual report with the SEC. Free follows 3 companies; Pro follows up to 500, and sorts and filters them.